Previous 10 | Next 10 |
Daré Bioscience (NASDAQ: DARE ) initiates a Phase 3 clinical trial, DARE-BVFREE , evaluating DARE-BV1 in women with bacterial vaginosis (BV). More news on: Daré Bioscience, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Carver Bancorp (NASDAQ: CARV ) +232% . More news on: Carver Bancorp, Inc., Urban One, Inc., Energous Corporation, Stocks on the move, , Read more ...
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center, double-blind, placebo-controlled Phase 3 clinical study of DARE-BV1 for the treatme...
SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the receipt by its wholly owned subsidiary of $1.5 million in additional grant funding from the Bill & Melinda Gates Foundation. The grant...
SAN DIEGO, June 04, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company will participate in the BIO International Convention, which will be held in a new, virtual event format for 2020, known...
Daré Bioscience, Inc. (DARE) Q1 2020 Results Earnings Conference Call May 14, 2020, 04:30 AM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants...
Dare Bioscience (NASDAQ: DARE ): Q1 GAAP EPS of -$0.18 beats by $0.15 . More news on: Daré Bioscience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Conference Call Today at 4:30 p.m. Eastern Time SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2020 and provided a company ...
SAN DIEGO AND DURHAM, N.C., May 11, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and d...
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2020, to review its fi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-01 09:02:05 ET Dare Bioscience Inc (DARE) announced stock split at a ratio of 1-for-12 on 2024-07-01 ... Full story available on KlickAnalytics.com
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split...
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (FSAD), particularly in an exploratory subset of women with FSAD with or without concomitant decreased desire There are currently no FDA-approved therapies fo...